idea-015 · viability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the investor, and the operator who has to run this as a business.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-015.md. The number is the claim's position in its ## Claims list, and the tag is copied from that claim as it stands at build time, never adjusted here. A [no claim] marker means nothing in the file speaks to the condition. No number appears here that isn't in a claim, and there is no ask slide. Where another lens holds a condition, this deck points at that deck rather than restating it. See docs/deck-spec.md.
What the file looks like from this chair. The device price the file first carried, $69-$89 under A4561 (a HCPCS code for a supply), is refuted: CMS (Centers for Medicare & Medicaid Services) prices A4561 at under a third of that. The file's notes now hold a narrower, sourced figure: $70.81-$73.34 under A4562, the Medicare allowed amount, paid once per reusable device, with the DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) supplier's margin and the patient's coinsurance both inside it. But no claim line tagged verified gives this device that figure. The Verifier's 2026-09-29 pass on the viability conditions earlier builds put on record came back unconfirmed on every one. Most important is claim 41unconfirmed: the A4562 descriptor fits a silicone device, but nobody has assigned the code to it, and no coverage policy in the cached index names A4562. The file's Stage 5 notes name the same open question for both floor-level money factors: what the silicone device itself is paid, and whether it is covered. The Scores table's draft TAM (total addressable market) row still multiplies by the refuted range. That is the Scorer's, and it is noted here only so no reader carries that arithmetic forward. This build appended nothing: every condition below already has a claim line.
Would have to be true: Medicare Part B (Medicare Part B) would have to pay twice, through two separate channels. The fitting service would be paid to the practice by the local Part B MAC (Medicare administrative contractor) under the Physician Fee Schedule. The device would be paid separately by a DME MAC (durable medical equipment Medicare administrative contractor) to whoever dispenses it, whether that is a DMEPOS supplier or the fitting practice enrolled as one. Commercial plans and state Medicaid would have to pay on terms close enough to Medicare's that the fittings outside Medicare fee-for-service are revenue too.
Where it stands: The fitting half is confirmed: CPT (Current Procedural Terminology) 57160 is an active code paid under the PFS (physician fee schedule), at about $70.48 non-facility, national and unadjusted claim 8verified. The device half is not. That the device is billed to a DME MAC separately from the fitting is unconfirmed, and no connector reaches the claims-processing manual claim 7unconfirmed. CMS files A4561/A4562 under the prosthetics & orthotics benefit category, not durable medical equipment, and the Verifier says that difference matters for coverage rules claim 6unconfirmed. Whether the fitting practice can be its own supplier resolved in part: 42 CFR 424.57(a) defines a DMEPOS supplier as an entity or individual "including a physician", so the same-entity premise has regulation text behind it. Open are whether a given practice meets the supplier standards and accreditation, and whether A4562 dispensed at a physician visit goes to the DME MAC as a supplier claim or to the Part B MAC incident to the visit. The billing half also inherits claim 41unconfirmed's unresolved code assignment claim 42unconfirmed. The only volume the file carries is Medicare fee-for-service, 73,363 fittings, and it is a floor claim 10verified. Parity from non-Medicare payers has one side only, because every reimbursement connector here reads Medicare files claim 30unconfirmed.
What would settle it: For claims 6 and 7, a human reading of the Medicare Claims Processing Manual's DMEPOS chapter and the DME MAC supplier manuals. For claim 42unconfirmed, a human reading of the 42 CFR 424.57(c) supplier standards and 424.58 accreditation rules against a real practice, and of the DME MAC jurisdiction rules for physician-dispensed supplies. For claim 30unconfirmed, state Medicaid fee schedules or a licensed commercial rate dataset, attached by a human.
If it's false: If the device is absorbed into the office-visit payment, nobody pays for it separately. The manufacturer then sells to practices out of practice operating budgets, at a price no claim in this file carries, and Slides 2 and 3 change completely. If there is a supplier between manufacturer and patient and the practice cannot be that supplier, a DMEPOS channel partner is part of the go-to-market plan and takes a margin inside the ceiling.
Would have to be true: Three things would have to hold. The adjustable device would have to be billed under an active HCPCS (Healthcare Common Procedure Coding System) code with its own fee, specifically A4562. The allowed amount under that code would have to leave room for a manufacturer after the supplier's margin. And no DME MAC coverage policy would impose a prior-authorisation or failed-alternative requirement that this device can't meet.
Where it stands:
unconfirmed because the claim also asserts a DME (durable medical equipment) benefit category and a bundling rule that the lookups do not support claim 6unconfirmed.
refuted, but the Verifier did not carry that onto the tag, because the cached file cannot link DME MAC articles to codes. The Verifier also flagged a weaker real signal: no current article title mentions a pessary. So the claim may be false as worded, in the sense that there may be no pessary-specific policy at all claim 31unconfirmed.
What would settle it: A coding verification for the actual device from the Medicare DMEPOS coding contractor, requested by a human once a device exists (claim 41unconfirmed). The Medicare Coverage Database LCD export cached with DME MAC code linkage, or a human reading the four DME MAC jurisdictions' policy lists and supplier manuals (claim 31unconfirmed). The payment amount per code needs nothing more: the fee schedule has answered it.
If it's false: If the device lands under A4561, the ceiling is about $29, and the business described in this file does not exist at that price. If it gets a miscellaneous code, the price is set by the contractor, and nothing in the file carries that price. Factor 2 and Factor 3 both move, and so does claim 24unconfirmed's margin question on Slide 7.
Would have to be true: Four factors would each have to be large enough, and they would have to be multiplied separately, not rolled into one headline figure: the women with symptomatic prolapse who choose a pessary, the rate at which they are fitted, the price per device, and the share of fittings a single-SKU adjustable device can reach.
Where it stands:
What would settle it: Price follows coding (Slide 2). The replacement interval needs a published pessary-longevity or replacement-cadence source, or a DME MAC same-or-similar and replacement rule read by a human. Reachable share needs practice-level research commissioned by a human, not a market report.
If it's false: Only the volume factor is verified, and it is a floor. The market is volume times a once-per-device ceiling that depends on an unassigned code, times an unknown share. If the share or the replacement cadence is small, the market is small, whatever the volume.
Would have to be true: The device would have to reach first sale without a clinical investigation: substantial equivalence on geometry and materials, backed by bench and biocompatibility testing, through a 510(k) (premarket notification) or an exemption and not a De Novo (De Novo classification request). The cost and calendar of that sequence would have to be small enough to recover from a once-per-device fee near A4562's.
Where it stands: Which of the three routes is live is unresolved. The 510(k)-versus-exempt question can't be answered by the classification connector claim 2unconfirmed. A De Novo reading stays live because no cleared adjustable-diameter predicate was found, though that is absence of evidence over a bounded search claim 5unconfirmed. Entry without clinical data is unconfirmed, and the precedent is mixed. The regulation says only "Class II (FDA device class II) (performance standards)" with no special-controls text naming clinical data. The Verifier read three HHW clearance summaries directly, as context and not as a tag basis, because clearance-summary still crashes. K231786 (an FDA 510(k) clearance number) (Gynethotics, clinician-set "personalized configurations") lists only mechanical testing, ISO (International Organization for Standardization) 10993 biocompatibility, TSST-1, cleaning and packaging validation, with no clinical testing. K232677 (Reia, a novel collapsible mechanism) includes a prospective single-arm clinical study at seven US sites. Which precedent FDA (US Food and Drug Administration) applies to a ratcheting, lockable diameter is the open question claim 34unconfirmed. Cleaning validation and ISO 10993 work on a mechanical joint is the named hidden cost claim 25unconfirmed. No claim in the file carries a development cost, a headcount or a calendar, and this deck supplies none [no claim]. Desirability Slide 5 raises a further cost: clinicians may need comparative clinical data even if FDA does not claim 38unconfirmed.
What would settle it: An FDA Product Classification database record for HHW read for its 510(k)-exempt flag, by a human or through a connector change (claim 2unconfirmed). An FDA pre-submission asking whether the locking diameter stays inside HHW and which of the two precedents applies (claims 1, 5, 34). A re-run of clearance-summary once the environment's pypdf/cryptography fault is fixed, so claim 34unconfirmed has a connector result and not only a direct read. A cost and calendar can only come from a human-built development plan.
If it's false: A De Novo reading adds years, as the Scores table notes, and a clinical study on the K232677 pattern adds more. The Factor 7 draft score assumed the cheap route. A slow, costly route against a ceiling of about $71-$73 per device may not pay back.
Would have to be true: The ratcheting, lockable diameter mechanism would have to be patentable over the published art. An incumbent like the one behind K231786, which covers a whole multi-size ring line in one 510(k), would have to be unable to add a lockable adjustable diameter to that line without a new 510(k) and the time that costs.
Where it stands: Patentability is a legal judgment no connector makes. The only checkable piece is that the deflatable-pessary patent is expired prior art, and that is confirmed claim 32unconfirmed. That expired disclosure cuts against a moat as much as it helps FTO (freedom to operate) claim 17verified. No landscape search on the locking mechanism has been done claim 18unconfirmed. The rule requiring a new 510(k) for a change that "could significantly affect the safety or effectiveness" of a device is verified text. Whether this change counts as significant is FDA's reading in its device-modifications guidance, and the whole condition fails if HHW is exempt claim 33unconfirmed claim 2unconfirmed. K231786 already describes clinician-determined configurations "with greater degrees of freedom within the cleared ranges", so the incumbent closest to this idea may be a short step from it (Slide 6) claim 43unconfirmed.
What would settle it: A patentability opinion on the locking mechanism, from the same commissioned professional search FTO needs (claim 18unconfirmed). The exemption flag (claim 2unconfirmed). FDA's device-modifications guidance, read by a human against this specific change (claim 33unconfirmed).
If it's false: With no patent and no regulatory barrier, the moat is being first. In a category where one incumbent 510(k) already covers a full ring line claim 26verified, that means one line extension by an incumbent erases the product's distinction. Slide 6's competitive picture gets worse.
Would have to be true: Four things would have to hold. No cleared pessary would already offer a clinician-set, lockable, re-adjustable diameter, and in particular K231786's clinician-determined "personalized configurations" would have to be something other than what this device does. The patient-specific pessary already solving the refit problem in Canada would have to lack a US clearance, or not compete at a comparable price. The collapsible Reia pessary would have to be addressing a different problem. And there would have to be a reason why incumbent ring makers, one line extension away, have not done this.
Where it stands: The incumbent field is confirmed in part. K132313, K231786 and K232677 (Reia) are prolapse-pessary clearances in HHW, and K233548 is stress-incontinence only claim 26verified. No adjustable-diameter device was found, but only as a no-match over trade names in a bounded sweep, which is weak evidence of absence claim 5unconfirmed. That no patient-specific or 3D-printed pessary is cleared in HHW now has a probable counterexample. The Verifier found K231786 (Cosm Medical, 2024-03-06), whose summary says the key difference from its predicate is that its pessaries "allow for personalized configurations of certain shape features, as determined by the clinician". It uses neither "patient-specific" nor "3D-printed" and says nothing about manufacturing method, so whether it is a patient-specific pessary is a terminology and substantial-equivalence call for a human. If it is, the claim is false. The tag is not refuted because no connector call returned refuted claim 43unconfirmed. How K231786's clinician-determined configuration compares mechanically with an in-visit lock is not in the file [no claim]. Reia's early feasibility study is completed and Reia is now a cleared competitor claim 21unconfirmed. Patient-specific pessaries are deployed at 18 Canadian sites with published outcomes, in the same prior-failure group this device targets claim 20unconfirmed. Why CooperSurgical/Milex or Bioteque have not added an adjustable diameter: nothing in the file speaks to it [no claim].
What would settle it: For claim 43unconfirmed, a human reading of the K231786 summary, and its device description and labeling if obtainable, to decide whether "personalized configurations ... as determined by the clinician" is a patient-specific pessary, and when and how the configuration is set. The same reading answers how close K231786 sits to this device's mechanism. For incumbent intent, a human conversation or a product-literature review. No connector reads it.
If it's false: If K231786 is a clinician-personalised pessary already cleared in the US, this device's distinction narrows from "a fit the clinician sets" to "a fit the clinician sets and re-sets on one device in the visit", and the rescue-a-failed-fit pitch has a US competitor as well as the Canadian one with evidence (desirability Slide 5). If an incumbent has an adjustable design in development, Slide 5 has no moat left to defend. Factor 8 falls toward its floor either way.
Would have to be true: A contract manufacturer's unit-cost quote on the ratcheting silicone device would have to come in materially below what the manufacturer receives. That is the A4562 allowed amount, less the DMEPOS supplier's margin. And the device would have to be coded A4562.
Where it stands: The ceiling per code is fixed: A4562 is $70.81-$73.34 non-rural, and the refuted A4561 figure no longer applies claim 11refuted. The cost side has no BOM (bill of materials) and no quote claim 24unconfirmed. The supplier's margin inside the ceiling is not in the file [no claim]. The coding that makes A4562 the ceiling for this device has not been determined claim 41unconfirmed.
What would settle it: A commissioned contract-manufacturing quote on the ratchet-and-lock design, by a human. The file calls it a commissioned item and carries no cost for it. Then a coding verification, which needs a device to exist.
If it's false: If the mechanism costs anywhere near a fixed-size pessary's full allowed amount, the device loses money on every unit it bills once. No volume on Slide 3 fixes a negative unit margin. If the code comes out as A4561, the ceiling falls to about $29 and the inequality is against a much lower number.
Every condition above with nothing verified behind it, whether a [no claim] marker or a claim still short of verified. Read this slide first. All seven conditions are here. The verified claims cited (8, 10, 17, 26) back the fitting-fee half of Slide 1, the volume floor on Slide 3, and the incumbent field on Slides 5 and 6. None of them backs the condition its slide turns on.
Nothing on this deck is unverified any more. The seven viability claims earlier builds put on record (30 to 33, and 41 to 43) have all had a Verifier pass, and every one came back unconfirmed. Two came back with something a reader should weigh: claim 43unconfirmed has a probable counterexample, and claim 31unconfirmed's connector miss is a weak real signal that no pessary-specific policy exists.
If only one thing from this chair could be checked: whether the ratchet-and-lock silicone device can be made at a unit cost well below what reaches the manufacturer out of an A4562 allowed amount of $70.81-$73.34, billed once per reusable device claim 24unconfirmed. That ceiling is this device's only if the code is assigned claim 41unconfirmed.
Why this one: the refutation of claim 11refuted answered the price per code, and cost is the one side of the margin inequality nobody has looked at. Coverage, share and volume only matter if each unit clears a margin. Code assignment matters just as much but cannot be asked until a device exists, while a quote can be had without clinical work or an FDA decision.
Naming it is not a recommendation, a gate, or a kill.
_shared/plain-language.md